UNLIMITED TURBO BULL - MODERNA | Market Closed - Euronext Paris 17:30:01 14/06/2024 BST | ||
| 3.635 EUR | -14.17% |
|
| Current month | -2.68% | ||
| 1 month | +41.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 3.815 | -9.92% |
| 13/06/24 | 4.235 | -3.86% |
| 12/06/24 | 4.405 | -1.78% |
| 11/06/24 | 4.485 | +2.28% |
| 10/06/24 | 4.385 | -9.87% |
Real-time Euronext Paris
Last update June 14, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 9J12S | |
| ISIN | DE000SW9W1C9 |
| Date issued | 03/05/2024 |
| Strike | 100.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.46 € |
|---|---|
| Lowest since issue | 1.65 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- 9J12S Certificat